Sibannac, Inc (SNNC) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Sibannac, Inc stock $0.01, price $0.01, upside +5.0%, quality 26 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Sibannac, Inc. operates as a media and management services company. It serves businesses with online marketing, advertising, sales tracking, management consulting, and other informational services.
Show moreShow less
The company also provides accounting, and expense and labor management systems to assist in compliance in the regulated industry environment. Sibannac, Inc. is based in Phoenix, Arizona.
Stock analysis
Sibannac, Inc (SNNC) currently trades at $0.0050, while our model-based Fair Value estimate is $0.0053, so the stock looks roughly fairly valued today (gap 4.8%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.0053 (bear) to $0.0058 (bull), the price of $0.0050 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Sibannac, Inc reported revenue of $6.4K in FY2025 versus $157K in FY2021, a compound −55.1%/yr. Reported net income was −$391K in FY2025.
Key figures
Market cap $678K Micro · EPS (TTM) $−0.0100 · Return on equity −275% · Return on assets (EBIT) −47.3% · Operating margin −111,474% · Revenue growth (YoY) −97.4% · Free cash flow −$75.5K · Net debt $639K.
What moves the price
The share trades about 77% below its 52-week high and 47% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 5%, SNNC screens cheaper than that median.
Fair Value models
Bear$0.0053Fair Value $0.0053Bull$0.0058
Price $0.0050 · Upside +5.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+113.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−52.1%
Start year 2020 (pandemic)
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.8%
’08
’09
’10
’11
’13
’16
’20
’21
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−143.1% (2020) → −5,418.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 573 stocks
Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside+5.0% · Above median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−48.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−97.4% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)40· sector 20
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 33
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sibannac, Inc Fair Value". https://www.fairvalue-calculator.com/stock/SNNC
Frequently asked questions
Is Sibannac, Inc (SNNC) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $0.0053 versus a price of $0.0050, about +5% upside (fairly valued).
What is the fair value of SNNC?
Our model-based fair value for Sibannac, Inc is $0.0053 (as of Nov 1, 2026), built from audited fundamentals. The current price: $0.0050.
What is the quality score of SNNC?
Sibannac, Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sibannac, Inc (SNNC)?
Our model-based price target is the fair value of $0.0053 (as of Nov 1, 2026) from 1 valuation models. Cautious scenario $0.0053, optimistic scenario $0.0058. It is a calculation from audited fundamentals, not an analyst target.
What is the Sibannac, Inc stock forecast for 2026?
Our models put fair value at $0.0053, about +5% upside versus a price of $0.0050 (fairly valued). Cautious scenario $0.0053, optimistic scenario $0.0058. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sibannac, Inc (SNNC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sibannac, Inc it is $0.0053 per share (as of Nov 1, 2026), against a price of $0.0050. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sibannac, Inc stock overvalued or undervalued in 2026?
As of Nov 1, 2026, SNNC trades below its calculated fair value: price $0.0050, fair value $0.0053, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SNNC?
No. The price is what the market pays today ($0.0050); the fair value is what the company's own numbers justify ($0.0053). For Sibannac, Inc the two are $0.0003 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sibannac, Inc worth?
The market values Sibannac, Inc at about $678K (market capitalisation, as of Nov 1, 2026). Per share that is $0.0050; our models calculate a fair value of $0.0053 per share.
What do the bullish and bearish scenarios say about SNNC?
Our models span a range for Sibannac, Inc: cautious scenario $0.0053, base $0.0053, optimistic $0.0058 per share (as of Nov 1, 2026, price $0.0050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sibannac, Inc (SNNC)?
Balance-sheet figures for Sibannac, Inc (as of Nov 1, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is SNNC from its 52-week high?
Sibannac, Inc trades at $0.0050, about 77% below its 52-week high of $0.0220 and 47% above the low of $0.0034 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0053 is for.
Which stocks are comparable to Sibannac, Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sibannac, Inc stock attractive at the current price?
The data as of Nov 1, 2026: price $0.0050, calculated fair value $0.0053 (+5%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SNNC calculated?
We run Sibannac, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0053, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. Sibannac, Inc currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sibannac, Inc (SNNC)?
The closing price on Oct 30, 2026 was $0.0050. Our model-based fair value is $0.0053, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sibannac, Inc right now?
The price is below even our cautious bear case ($0.0053). The market is more pessimistic than our downside scenario. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0053 to $0.0058), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Sibannac, Inc
How large is the market capitalisation of Sibannac, Inc (SNNC)?
The market capitalisation of Sibannac, Inc is $678K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sibannac, Inc (SNNC)?
Earnings per share at Sibannac, Inc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sibannac, Inc (SNNC)?
The return on equity (ROE) of Sibannac, Inc is −275% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sibannac, Inc (SNNC)?
On an EBIT basis the return on assets of Sibannac, Inc is −47.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sibannac, Inc (SNNC)?
The operating margin of Sibannac, Inc is −111,474% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sibannac, Inc (SNNC)?
Revenue at Sibannac, Inc is growing −97.4% versus a year earlier (3y avg 0.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sibannac, Inc (SNNC) generate?
The free cash flow of Sibannac, Inc is −$75.5K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sibannac, Inc (SNNC) carry?
The net debt of Sibannac, Inc is $639K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sibannac, Inc in the live analysis
One click puts Sibannac, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Nov 1, 2026